Netherlands to Test Century-Old Tuberculosis Shot for Coronavirus
(Bloomberg) --
As evidence grows that a century-old tuberculosis vaccine can protect against respiratory infections, the Netherlands will begin testing it on thousands of frail elderly people who are at elevated risk in the coronavirus pandemic.
Two new studies point to promising results for the bacillus Calmette-Guerin shot, or BCG, against Covid-19, though research evaluating the vaccine's direct potential against the new virus is months away from publishing results.
One study, led by Mihai Netea of Radboud University Medical Center in the Netherlands, shows that elderly people who were vaccinated with BCG are 80% less likely than those without shots to get a respiratory tract infection. Another in a group of hospital workers in the United Arab Emirates shows those who got the shot didn't catch Covid-19, unlike an unvaccinated control group.
The Dutch project, which starts this week, aims to recruit as many as 7,000 elderly patients over the next two months, with results expected in six months at the most, said Netea, who's leading it along with Marc Bonten from the University Medical Center in Utrecht. As drugmakers' efforts to develop vaccines against the new coronavirus are still months from delivering, the older shot may help bridge the gap and protect those most at risk against severe infection.
“We hope this would help us take a decision regarding the pandemic before the end of the year,” Netea said in a telephone interview.
©2020 Bloomberg L.P.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.